# Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

> **NCT06401980** · PHASE2 · RECRUITING · sponsor: **Swiss Cancer Institute** · enrollment: 162 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT06401980
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2030-06
- **Final completion:** 2030-09
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401980, "Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06401980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*